drugset / Trial / NCT05376319
PR3-AAV Resilient Remission or PRRR
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (PR3-AAV).
Timeline
- Start
- 2023-06-30
- Primary completion
- 2024-05-07
- Completion
- 2024-05-07
Outcome
Outcome not reported
Stopped (Business): “Funding was withdrawn by sponsor.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |
| Comparator | Rituximab | Monoclonal antibody | 1000 mg | Intravenous |